NurExone Biologic (FRA:J90) Net Margin %: 0.00% (As of Mar. 2026)


FRA:J90 NurExone Biologic Inc FRA:J90
34 GF Score
Price €0.32
! 2 Warning Signs
View Full Analysis

What is NurExone Biologic Net Margin %?

NurExone Biologic FRA:J90 +2.54% 34 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:J90 with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 946 Biotechnology companies, NurExone Biologic ranks worse than 105708.14% on this metric.

Net margin is calculated as Net Income divided by its Revenue. NurExone Biologic's Net Income for the three months ended in Mar. 2026 was €-1.53 Mil. NurExone Biologic's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, NurExone Biologic's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for NurExone Biologic's Net Margin % or its related term are showing as below:


FRA:J90's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

NurExone Biologic  (FRA:J90) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

NurExone Biologic Net Margin % Related Terms

NurExone Biologic Net Margin % Historical Data

* Premium members only.

The historical data trend for NurExone Biologic's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NurExone Biologic Net Margin % Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
0.00 0.00 0.00 0.00 0.00

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:J90 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, NurExone Biologic's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Net Margin % distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Net Margin % falls into.


FRA:J90
34GF Score
NurExone Biologic Inc FRA:J90
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NurExone Biologic Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

NurExone Biologic's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-5.452/0
= %

NurExone Biologic's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.528/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
NurExone Biologic (FRA:J90) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on NurExone Biologic and its competitors. According to the industry distribution chart, NurExone Biologic ranks #999999 out of 946 companies in the Biotechnology industry.
Is NurExone Biologic's Net Margin % too high?
NurExone Biologic's current Net Margin % is 0.00%. Based on the distribution chart, NurExone Biologic ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NurExone Biologic has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, NurExone Biologic ranks #999999 out of 946 companies for Net Margin %. This places NurExone Biologic in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on NurExone Biologic and its competitors. NurExone Biologic's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. NurExone Biologic's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NurExone Biologic Business Description

Other Exchanges NRXBF:USANRX:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
34GF Score

Get the complete analysis for FRA:J90

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price